Voloridge Investment Management
PRME icon

Voloridge Investment Management’s Prime Medicine PRME Stock Holding History

Voloridge Investment Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23,121
Closed -$80.2K – 1223
2025
Q4 		$80.2K Sell
23,121
-146,900
-86% -$653K ﹤0.01% 1110
2025
Q3 		$942K Buy
+170,021
New +$691K ﹤0.01% 1047
2024
Q4 		– Sell
-27,119
Closed -$105K – 1332
2024
Q3 		$105K Sell
27,119
-18,634
-41% -$86.3K ﹤0.01% 1131
2024
Q2 		$235K Buy
+45,753
New +$277K ﹤0.01% 1165

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Voloridge Investment Management's PRME Position: Q1 2026 in Review

Voloridge Investment Management sold out of Prime Medicine (PRME) in Q1 2026, closing a stake of 23,121 shares — an estimated $80.2K sold.

Voloridge Investment Management first reported a position in PRME in Q2 2024 and held it in 4 quarters. The position peaked at $942K in Q3 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Voloridge Investment Management reported no remaining Prime Medicine position as of Q1 2026 after selling out during the quarter.
  • Voloridge Investment Management sold 23,121 Prime Medicine shares in Q1 2026, an estimated $80.2K.
  • Voloridge Investment Management first reported a position in Prime Medicine in Q2 2024 and held it in 4 quarters.
  • Voloridge Investment Management's Prime Medicine position peaked at $942K in Q3 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Voloridge Investment Management's 13F filing for Q1 2026, filed 15 May 2026.